On Nov 26, major Wall Street analysts update their ratings for $BridgeBio Pharma (BBIO.US)$, with price targets ranging from $45 to $55.
Goldman Sachs analyst Paul Choi maintains with a buy rating, and adjusts the target price from $50 to $55.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $45.
Citi analyst David Lebowitz maintains with a buy rating, and maintains the target price at $45.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $47 to $54.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $45.
Furthermore, according to the comprehensive report, the opinions of $BridgeBio Pharma (BBIO.US)$'s main analysts recently are as follows:
The FDA's approval of BridgeBio's stabilizer acoramidis as Attruby for ATTR-CM, coming before the anticipated November 29 PDUFA deadline, was celebrated as a significant achievement, marking the company's transition into a commercial entity with an optimal label. The potential for ATTR-CM remains, according to analysts, still largely underestimated.
Here are the latest investment ratings and price targets for $BridgeBio Pharma (BBIO.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
